Skip to Main Navigation Skip to Page Content

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Procarbazine hydrochloride: Target Organs and Levels of Evidence for TR-019

Bioassay of Procarbazine for Possible Carcinogenicity (CASRN 366-70-1)

Chemical (Study Title) CASRN	Peer Review Date	Route/Exposure Levels	Study Laboratory
Procarbazine hydrochloride 366-70-1	NA	Intraperitoneal Injection R: 0,15,30, M: 0,6,12 MG/KG/35 PER GROUP	Southern Research Institute

Levels of Evidence

Male Rats: Positive

Type	Organ/Tissue (Lesion)
Neoplastic Lesions	Hematopoietic System: (LYMPHOMA OR LEUKEMIA) Mammary Gland: (ADENOCARCINOMA) Brain: (ADENOCARCINOMA, NEUROBLASTOMA, CARCINOMA)

Female Rats: Positive

Type	Organ/Tissue (Lesion)
Neoplastic Lesions	Hematopoietic System: (LYMPHOMA) Mammary Gland: (ADENOCARCINOMA) Brain: (NEUROBLASTOMA)

Male Mice: Positive

Type	Organ/Tissue (Lesion)
Neoplastic Lesions	Hematopoietic System: (LYMPHOMA OR LEUKEMIA) Brain: (NEUROBLASTOMA) Lung: (ALVEOLAR/BRONCHIOLAR ADENOMA)

Female Mice: Positive

Type	Organ/Tissue (Lesion)
Neoplastic Lesions	Hematopoietic System: (LYMPHOMA OR LEUKEMIA) Lung: (ALVEOLAR/BRONCHIOLAR ADENOMA) Brain: (NEUROBLASTOMA) Uterus/Cervix: (ADENOCARCINOMA)